Adchnon
Adchnon Uses, Dosage, Side Effects, Food Interaction and all others data.
Adchnon is a hemostatic agent that promotes clotting, preventing blood loss from open wounds. It is an oxidation product of adrenaline which enhances the microcirculatory tone . In the future this may prevent excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on effectiveness and severity of side effects remains inconclusive. It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.
Adchnon has been investigated for use in the treatment of non-surgical acute uncomplicated hemorrhoids in a mixture with Troxerutin, and this combination therapy demonstrated efficacy and safe tolerability either at a local or systemic level .
Adchnon is an anti-bleeding agent that increases platelet aggregation and forms a platelet plug by interacting with α-adrenoreceptors on surface of platelets . It is shown to improve the structure of local capillary vessels in haemorrhage caused by fragility of capillaries. Adchnon capillary stabilizer that reverses pulmonary vascular hyperpermeability and decreases arterial PaO2 in experimental models .
| Trade Name | Adchnon |
| Generic | Carbazochrome |
| Carbazochrome Other Names | Adchnon, Adedolon, Adrenostan, Carbazochrom, Carbazochrome, Carbazochromum, Carbazocromo |
| Type | |
| Formula | C10H12N4O3 |
| Weight | Average: 236.231 Monoisotopic: 236.090940262 |
| Groups | Experimental, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Indicated for capillary and parenchymal hemorrhage (trauma, tonsillectomy, during surgery), intestinal bleeding, and thrombocytopenic purpura.
Adchnon is also used to associated treatment for these conditions: Venous Insufficiency
How Adchnon works
Adchnon interacts with platelet surface α-adrenoreceptors which are Gq-coupled receptors that leads to activation of PLC IP3/DAG pathway and increase in intracellular calcium levels. Elevated calcium ions bind to calmodulin and activates Ca2+/calmodulin-dependent myosin light chain kinase, allowing the myosin crossbridge to bind to the actin filament and polymerisation of globular actin (G-actin) to filamentous actin (F-actin) . Subsequent contraction of endothelial cells changes the shape of platelets and promotes the release of factors such as serotonin, ADP, Von Willebrand and platelet activating factor by platelets that induce aggregation and platelet adherence . Adchnon is reported to inhibit vascular hyperpermeability by inhibiting agonist-induced phosphoinositides hydrolysis caused by various vasoactive agents such as tryptase, thrombin and bradykinin .
Innovators Monograph
You find simplified version here Adchnon
